Abstract:The discovery of incretin mimetics represents a major turning point in obesity and diabetes medicine. These small molecules are agonists of one or more receptors of glucagon, GLP-1, and GIP. Despite their efficacy and widespread use, the mechanism for the reduction in bodyweight has not been elucidated. Energy homeostasis is regulated in the hypothalamus and hindbrain, where incretin receptors are also expressed, leading to the hypothesis that incretin mimetics act in these brain regions to exert their appetite suppressing effects. The aim of this study is to identify mechanisms of action in the hypothalamus and hindbrain of GLP-1 and GIP agonists.Adult, diet-induced obese male CL57BL/6-J mice were injected IP with vehicle, GLP-1R agonist, GIPR agonist, GIPR antagonist, and MAR709, a mouse and human GLP-1R/GIPR dual-agonist, n=6. 8h after injection, the hypothalamus and hindbrain were collected and single-nuclei RNA and ATAC (assay for transposase-accessible chromatin) sequencing was performed, yielding 211537 hypothalamic and 57844 hindbrain nuclei after pre-processing (removal of low-quality nuclei & doublets).Cell type annotations from the Allen Institute mouse brain atlas were transferred to this data using correlation mapping. To identify cell types acted on by the incretin agonists, cell types were ranked by transcriptional and accessible chromatin changes between groups using Pertpy. Differences in intercellular communication were identified using a novel atlas-informed cell-cell communication method.We have generated the largest single-cell multiome dataset in the hindbrain and hypothalamus to date and identified gene expression and gene regulatory changes by which GIP and GLP-1 mimetics act to exert their anti-obesity effects. These data and analysis identified candidate mechanisms of action of incretin-mediated weight loss. Disclosure R.M. Gutgesell: None. G. Maity-Kumar: None. C. Garcia Caceres: None. M.H. Tschöp: Consultant; Boeher Inglehim. T.D. Müller: Stock/Shareholder; Novo Nordisk, Eli Lilly and Company. Research Support; Novo Nordisk. Speaker's Bureau; Novo Nordisk, Merck & Co., Inc., Eli Lilly and Company, Novo Nordisk.

Signaling profiles in HEK 293T cells co-expressing GLP-1 and GIP receptors

Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors

Structural basis for the therapeutic advantage of dual and triple agonists at the human GIP, GLP-1 or GCG receptors

Role of Peroxisome Proliferator-Activated Receptor Gamma in Glucose-Induced Insulin Secretion

Control of insulin secretion by GLP-1

Insights into agonist-elicited activation of the human glucose-dependent insulinotropic polypeptide receptor

Dynamics of GLP-1R peptide agonist engagement are correlated with kinetics of G protein activation

Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors

Molecular Insights into Ago-Allosteric Modulation of the Human Glucagon-Like Peptide-1 Receptor

Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists

Biased Signaling of Gpcr Regulates Pancreatic Beta Cell Secretion and Survival

Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism

The role of G protein-coupled receptor kinases in GLP-1R β-arrestin recruitment and internalisation

Structural Analysis of the Dual Agonism at GLP-1R and GCGR

Molecular basis of enhanced GLP-1 signaling mediated by GLP-1(9-36) in conjunction with LSN3318839

Tirzepatide, GIP(1-42) and GIP(1-30) display unique signaling profiles at two common GIP receptor variants, E354 and Q354

Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls

ER stress and unfolded protein response (UPR) signaling modulate GLP-1 receptor signaling in the pancreatic islets

Endogenous cell membrane interactome mapping for the GLP-1 receptor in different cell types

Structure and Molecular Mechanism of Signaling for the Glucagon-like Peptide-1 Receptor Bound to Gs Protein and Exendin-P5 Biased Agonist

105-OR: Single-Cell Multiomic Analysis of the Effect of GIP and GIP-1 Mono- and Multi-agonism on the Hypothalamus and Hindbrain